LBLinda Boldrup

Linda Boldrup

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Boldrup has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low potential of circulating interleukin 1 receptor antagonist as a prediction marker for squamous cell carcinoma of the head and neck

    by Linda Boldrup, Philip Coates, Xiaolian Gu, Lixiao Wang, Robin Fåhraeus, Torben Wilms, Nicola Sgaramella, Karin Nylander

    Background: Circulating markers are attractive molecules for prognosis and management of cancer that allow sequential monitoring of patients during and after treatment. Based on previous protein profiling data, circulating interleukin 1 receptor antagonist (IL‐1Ra) was evaluated as a potential diagnostic and prognostic marker for squamous cell carcinomas of the head and neck (SCCHN). In this study, we aimed at confirming the clinical relevance of plasma IL‐1Ra in SCCHN and exploring its potential as a prediction marker for SCCHN.Methods: Plasma from 87 patients with SCCHN, control plasma from 28 healthy individuals and pre‐diagnostic plasma from 44 patients with squamous cell carcinoma of the oral tongue (SCCOT) and 88 matched controls were analysed with IL‐1Ra electrochemiluminescence immunoassays from mesoscale diagnostics.Results: Plasma IL‐1Ra was found to be up‐regulated in patients with oral tongue, gingiva and base of tongue tumours compared to healthy individuals (p < 0.01). IL‐1Ra levels positively correlated with tumour size (p < 0.01) and body mass index (p = 0.013). Comparing pre‐diagnostic plasma to the matched controls, similar IL1‐Ra levels were seen (p = 0.05).Conclusion: The anti‐inflammatory cytokine IL‐1Ra could be a diagnostic marker for SCCHN, whereas its potential as a cancer prediction marker was not supported by our data.


  • Open Access

    PD‐L1 in squamous cell carcinoma of the oral tongue shows gender‐specific association with prognosis

    by Torben Wilms, Xiaolian Gu, Linda Boldrup, Philip J. Coates, Robin Fahraeus, Lixiao Wang, Nicola Sgaramella, Niels‐Hilmer Nielsen, Lena Norberg‐Spaak, Karin Nylander

    Objective: To use alternative quantitation approaches to clarify the clinical implication of programmed cell death ligand 1 (PD‐L1) in squamous cell carcinoma of the oral tongue (SCCOT).Materials and Methods: Ventana SP263 immunohistochemistry assay and a multiplicative QuickScore method were applied to quantify PD‐L1 in tumor and surrounding immune cells from 101 patients with SCCOT. Tumor‐infiltrating immune cells were estimated from bulk tissue transcriptional profiles of 25 patients. Circulating PD‐L1 levels were measured in serum from 30 patients using an electrochemiluminescence assay platform.Results: We found higher tumor cell PD‐L1 levels in females than males (p = .019). For patients with low PD‐L1 in tumor cells, better survival was seen in males than females (overall survival p = .021, disease‐free survival p = .020). Tumor‐infiltrating natural killer T cells, immature dendritic cells, and M1 macrophages were positively associated with tumor cell PD‐L1 (p < .05).Conclusions: Our data confirmed the significance of gender on tumor cell PD‐L1 expression and demonstrated combined effects of gender and PD‐L1 levels on clinical outcome in patients with SCCOT. The data also indicated the involvement of specific immune cell types in PD‐L1‐regulated immune evasion.